Home > Focus Areas > Leukemia and Lymphoma Connect > Post
2yr
Efficacy of front-line immunochemotherapy for transplant-ineligible mantle cell lymphoma: A network meta-analysis of randomized controlled trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37264757/
Our study presents the most promising first-line treatment strategy for transplant-ineligible MCL patients in terms of PFS and OS, which provides innovative treatment strategy for MCL treatment.
Conclusions: Our study presents the most promising first-line treatment strategy for transplant-ineligible MCL patients in terms of PFS and OS, which provides innovative treatment strategy for MCL treatment.
• Source: Cancer Medicine
• Conclusions/Relevance: “Our study presents the most promising first-line treatment strategy for transplant-ineligible MCL patients in terms of PFS and OS, which provides innovative treatment strategy for MCL treatment.”
• In the current network meta-analysis (NMA), 9 studies were included representing 2987 MCL patients. Among other findings, the BR-Ibrutinib+R (bendamustine, rituximab, ibrutinib, and rituximab maintenance) demonstrated the best PFS, while VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone) had the most potential to improve OS. The BR regimen attained a better PFS vs. R-CHOP.
• “Our findings suggest that BR-Ibrutinib+R regimen could be the first choice for improving the PFS of MCL patients who are not candidates for transplantation in first-line treatment. VR-CAP regimen may be better than other options in improving OS in MCL patients. These results suggest that a regimen containing novel antitumor agents improves outcomes in patients with MCL. There are also many new antitumor drugs in the pipeline that hope to shed new light on the survival of MCL patients,” the authors wrote.
• Limitations of the current NMA include no consideration of adverse events, a limited number of included studies, and no analysis of maintenance after 1L treatment.